We only have this paper's title and publication details.
Read it at the sourcePreclinical study demonstrates varying PD-1 inhibitor efficacy across triple-negative breast cancer mouse models, indicating early T-cell shifts predict therapeutic response.
No takes yet. Share an insight, caveat, or question.
Katuwal et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: